Zachary Zimmerman

Zachary Zimmerman is the CEO and Co-Founder of Blacksmith Medicines, a company that specializes in developing metalloenzyme-targeted medicines. Zachary is also a Co-Founder and Director at Forge Therapeutics, Inc., an early stage biotechnology company focused on discovering novel antibiotics. Prior to these roles, Zachary held positions at companies such as Arcturus Therapeutics, Regulus Therapeutics, Alnylam Pharmaceuticals, and IDC. Zachary holds a Ph.D. in Cell/Cellular and Molecular Biology from the University of California, Santa Cruz, as well as a post-doc in Cancer Biology from Stanford University.